<DOC>
	<DOCNO>NCT01389895</DOCNO>
	<brief_summary>This study multicenter , randomize , double-blind , placebo-controlled , multiple dose study approximately 24 subject SCLE enrol . Cohort 1 consist 12 subject ( 6 AMG 557 : 6 placebo ) randomize receive AMG 557 210 mg match placebo . Cohort 2 consist 12 subject ( 6 AMG 557 : 6 placebo ) randomize receive AMG 557 140 mg match placebo . Enrollment Cohort 2 ( 140 mg ) initiate enrollment Cohort 1 ( 210 mg ) complete .</brief_summary>
	<brief_title>Safety Study AMG 557 Subjects With Subacute Cutaneous Lupus Erythematosus</brief_title>
	<detailed_description>Cohort 1 consist 12 subject ( 6 AMG 557 : 6 placebo ) randomize receive AMG 557 210 mg match placebo . Cohort 2 consist 12 subject ( 6 AMG 557 : 6 placebo ) randomize receive AMG 557 140 mg match placebo . Enrollment Cohort 2 ( 140 mg ) initiate enrollment Cohort 1 ( 210 mg ) complete . After Cohort 1 2 enrollment complete , emerge PK PD data review determine additional 4-8 subject SCLE enrol study address equivocal result study . These 4-8 additional subject receive dose either 210 mg 140 mg SC ( allocation ratio 1 AMG 557 : 1 placebo ) . In addition , open label extension study participant study may institute follow completion analysis result study . Initiation study require acceptable risk-benefit profile evidence efficacy observe current study .</detailed_description>
	<mesh_term>Lupus Erythematosus , Cutaneous</mesh_term>
	<criteria>Men woman , age 18 70 year age , inclusive , time randomization ; Body mass index 18 35 kg/m2 screening ; Diagnosis subacute cutaneous lupus erythematosus ( SCLE ) without systemic lupus erythematosus ( SLE ) . SCLE define Gilliam Sontheimer classification ( J Am Acad Dermatol 1981 ; 4 ( 4 ) :471475 ) . SLE define recent American College Rheumatology criterion , include positive antinuclear antibody ( ANA ) screen document history ( least 1:80 indirect immunofluorescent assay ) ; A history skin biopsy consistent diagnosis SCLE ; Positive SSA and/or SSB antibodies screen ; Intolerance antimalarial therapy ≥ 3 month antimalarial therapy residual disease activity define : least 2 area least level 2 erythema 3 area least level 1 erythema use cutaneous lupus erythematosus disease area severity index ( CLASI ) . The total CLASI activity must ≥ 10 ; Subject must stable disease activity 3 month prior screen clinical judgment Principal Investigator ( PI ) anticipate change therapy ; Stable dose topical steroid strong mediumpotency ( Class III Class VII ) ≥ 2 week screen permit ; Prednisone ≤ 10 mg/day ( equivalent ) permit ; Stable dos methotrexate ≤ 20 mg/week , azathioprine ≤ 150 mg/day , 6mercaptopurine ≤ 150 mg/day 12 week prior screen permit . Druginduced SCLE ; Any disorder ( include psychiatric ) , condition clinically significant disease ( diagnosis SCLE , SLE , Sjögren 's syndrome ) would , progressive nature and/or severity , interfere study evaluation , completion and/or procedure per investigator 's discretion . This include age related comorbidities presence congestive heart failure , angina , chronic obstructive pulmonary disease , asthma ; Presence history vasculitis ( comprise internal organ extremity lead peripheral neuropathy ) within last 3 year , presence history active Central Nervous System ( CNS ) lupus ( defined seizure disorder , cerebral vascular accident , psychosis ascribe SLE , encephalitis , meningitis , myelitis ) require therapy within last 3 year ; History malignancy ; Signs symptoms viral , bacterial fungal infection within 30 day study randomization , recent history repeat infection ; Underlying condition SCLE , SLE , Sjögren 's syndrome predispose one infection ( eg , history splenectomy ) ; Administration &gt; 10 mg/day prednisone ( equivalent ) 30 day prior randomization ; Prior use follow biological agent : Rituximab , LymphostatB , TAClIg , CTLA4Ig ; Current treatment ( within 3 month 5 halflives screen ) thalidomide , mycophenolate mofetil , cyclosporine , tacrolimus , sirolimus , Intravenous ( IV ) immunoglobulin , plasmapheresis , oral IV cyclophosphamide ; Receiving receive investigational drug ( currently use investigational device ) within 30 day 5 halflives ( whichever longer ) , prior receive first dose study medication ) . 29 . Use overthecounter prescription medication within 14 day 5 halflives ( whichever longer ) , prior receive first dose study medication . Acetaminophen ( 2 g per day ) analgesia hormone replacement therapy ( eg , estrogen , thyroid ) allow . In addition , prescription drug hypertension hypercholesterolemia , oral hypoglycemic drug , NSAIDs allow ; however , NSAIDS permit within 24 hour skin biopsy reduce risk bleeding . Other medication may approve follow review Principal Investigator Amgen Medical Monitor . Written documentation review Amgen acknowledgement require subject participation ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Lupus</keyword>
	<keyword>Cutaneous lupus</keyword>
</DOC>